文献速递胸部肿瘤

PD-(L)1抑制剂单药对比化疗联合免疫治疗用于高表达PD-L1的晚期非小细胞肺癌:系统综述与荟萃分析

PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis.
PubMed 文献 · JAMA Oncol · 2026-01-01

该研究系统检索了截至2025年8月3日的3期随机对照试验,纳入24项试验共5546例PD-L1高表达晚期NSCLC患者,比较PD-(L)1抑制剂单药与化疗联合免疫治疗对比单纯化疗的疗效。结果显示,化疗联合免疫治疗相比单药在总生存和无进展生存上均显著更优,重建个体患者数据分析亦显示化疗联合免疫治疗的中位OS和中位PFS均更长。

要点

  • 在PD-L1≥50%的晚期NSCLC中,化疗联合免疫治疗较PD-(L)1抑制剂单药显著改善OS和PFS
  • 重建个体数据显示化疗联合免疫治疗中位OS为29.2个月,单药为19.8个月
  • 化疗联合免疫治疗中位PFS为11.3个月,单药为6.8个月

核心结论

  • 在PD-L1高表达的晚期NSCLC初治患者中,化疗联合免疫治疗相较PD-(L)1抑制剂单药与显著更优的OS和PFS相关。
  • 上述发现需前瞻性试验确认。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Embase及主要肿瘤学会议汇编中截至2025年8月3日发表的3期随机对照试验。
  • 纳入24项试验共5546例PD-L1高表达晚期NSCLC患者,其中16项评估化疗联合免疫治疗,8项评估PD-(L)1抑制剂单药。
  • 提取OS和PFS的风险比(HR),采用逆方差法合成,并行荟萃回归、网状荟萃分析及基于已发表Kaplan-Meier曲线重建个体患者数据。

主要发现

  • 对比单纯化疗,化疗联合免疫治疗改善OS(HR 0.63,95%CI 0.56-0.72,P<.001)和PFS(HR 0.44,95%CI 0.39-0.49,P<.001)。
  • 对比单纯化疗,PD-(L)1抑制剂单药亦改善OS(HR 0.74,95%CI 0.69-0.80,P<.001)和PFS(HR 0.70,95%CI 0.65-0.76,P<.001)。
  • 亚组差异检验提示化疗联合免疫治疗相较单药获益更优(OS:χ21=4.1,P=.04,I2=75.8%;PFS:χ21=48.1,P<.001,I2=97.9%)。
  • 荟萃回归分析示OS HR 0.85(95%CI 0.72-1.00,P=.048)、PFS HR 0.61(95%CI 0.50-0.75,P<.001);网状荟萃分析示OS HR 0.85(95%CI 0.73-0.99)、PFS HR 0.61(95%CI 0.50-0.75)。
  • 重建个体患者数据分析示化疗联合免疫治疗(n=704)相比单药(n=1706)中位OS为29.2个月(95%CI 25.2-35.4)对19.8个月(95%CI 18.3-21.7),HR 0.74(95%CI 0.66-0.82,P<.001);中位PFS为11.3个月(95%CI 10.3-13.5)对6.8个月(95%CI 6.2-7.1),HR 0.67(95%CI 0.60-0.75,P<.001)。

临床怎么用

  • 对于PD-L1高表达的晚期NSCLC初治患者,化疗联合免疫治疗在OS和PFS上均优于PD-(L)1抑制剂单药,可作为优先考虑的方案。
  • PD-(L)1抑制剂单药仍是有效选择,但需结合患者体能状态、化疗耐受性及治疗目标个体化决策。

局限性

  • 结论基于荟萃分析,需前瞻性试验确认。
  • 重建个体患者数据来源于已发表Kaplan-Meier曲线,可能存在信息偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: For patients with advanced non-small cell lung cancer (NSCLC) and programmed cell death 1 ligand 1 (PD-L1) expression of 50% or higher, programmed cell death 1 protein or PD-L1 (PD-[L]1) inhibitor monotherapy is commonly used as first-line therapy; however, whether adding chemotherapy improves outcomes in this population remains unknown. OBJECTIVE: To compare overall survival (OS) and progression-free survival (PFS) associated with PD-(L)1 inhibitor monotherapy vs chemoimmunotherapy in treatment-naive patients with advanced NSCLC and high PD-L1 expression. DATA SOURCES: PubMed, Embase, and major oncology conference proceedings were searched for phase 3 randomized clinical trials (RCTs) published before August 3, 2025. STUDY SELECTION: Eligible studies were phase 3 RCTs that enrolled patients with untreated advanced NSCLC, evaluated PD-(L)1 inhibitor monotherapy or chemoimmunotherapy vs chemotherapy alone, and reported outcomes in patients with high PD-L1 expression. DATA EXTRACTION AND SYNTHESIS: Hazard ratios (HRs) for OS and PFS were extracted from published studies and synthesized using inverse variance methods. Additional analyses included meta-regression, network meta-analysis, and reconstructed individual patient data from published Kaplan-Meier curves. MAIN OUTCOMES AND MEASURES: Primary outcome was OS; secondary outcome was PFS. RESULTS: Among 24 trials including 5546 patients with PD-L1-high NSCLC, 16 evaluated chemoimmunotherapy and 8 PD-(L)1 inhibitor monotherapy. Compared with chemotherapy, survival was improved by both chemoimmunotherapy (OS: HR, 0.63 [95% CI, 0.56-0.72]; P < .001; PFS: HR, 0.44 [95% CI, 0.39-0.49]; P < .001) and PD-(L)1 inhibitor monotherapy (OS: HR, 0.74 [95% CI, 0.69-0.80]; P < .001; PFS: HR, 0.70 [95% CI, 0.65-0.76]; P < .001). Tests for subgroup differences suggested improved benefit with chemoimmunotherapy compared to PD-(L)1 inhibitor monotherapy (OS: χ21 = 4.1; P = .04; I2 = 75.8%; PFS: χ21 = 48.1; P < .001; I2 = 97.9%), consistent with meta-regression analyses (OS: HR, 0.85 [95% CI, 0.72-1.00]; P = .048; PFS: HR, 0.61 [95% CI, 0.50-0.75]; P < .001) and network meta-analyses (OS: HR, 0.85 [95% CI, 0.73-0.99]; PFS: HR, 0.61 [95% CI, 0.50-0.75]). In the reconstructed individual patient data analysis, median OS was longer with chemoimmunotherapy (n = 704 patients) compared to PD-(L)1 inhibitor monotherapy (n = 1706 patients) (29.2 months [95% CI, 25.2-35.4] vs 19.8 months [95% CI, 18.3-21.7]; HR, 0.74 [95% CI, 0.66-0.82]; P < .001). Similarly, median PFS was significantly longer with chemoimmunotherapy (n = 701 patients) compared to PD-(L)1 inhibitor monotherapy (n = 1706 patients) (11.3 months [95% CI, 10.3-13.5] vs 6.8 months [95% CI, 6.2-7.1]; HR, 0.67 [95% CI, 0.60-0.75]; P < .001). CONCLUSIONS AND RELEVANCE: In this meta-analysis of phase 3 RCTs, chemoimmunotherapy was associated with significantly improved OS and PFS compared with PD-(L)1 inhibitor monotherapy in patients with advanced NSCLC and high PD-L1 expression. Prospective trials are needed to confirm these findings.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Di Federico A, Compagno S, Mantuano F, et al. PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis. JAMA Oncol. 2026. PMID: 42240993. doi:10.1001/jamaoncol.2026.1548

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。